Multiple proliferation-survival signalling pathways are simultaneously active in BRAF V600E mutated thyroid...

Area of Science:

• Oncology
• Molecular Biology
• Cell Signaling

Background:

• BRAF is a key oncogene in thyroid carcinoma pathogenesis.
• The BRAF V600E mutation is frequently observed in thyroid cancers.

Purpose of the Study:

• To investigate the activation status of BRAF and AKT kinase signaling pathways in BRAF V600E mutated thyroid carcinoma cells.
• To determine if downstream signaling pathways are active in these cancer cells.

Main Methods:

• Screening of five thyroid carcinoma cell lines and one non-cancer cell line for BRAF V600E mutation status using immunofluorescent staining and Western blot.
• Testing the activation status of ERK and AKT kinase proteins in BRAF V600E mutated cell lines via immunofluorescent studies and Western blots.

Main Results:

• BRAF V600E mutated protein expression was confirmed in four thyroid carcinoma cell lines.
• Active ERK and active AKT kinase proteins were detected in these BRAF V600E mutated thyroid carcinoma cells.

Conclusions:

• BRAF V600E mutated thyroid carcinomas exhibit active ERK and AKT kinase signaling.
• These active pathways stimulate downstream signaling, promoting cancer cell proliferation and survival.
• Targeting multiple pathways may be crucial for effective molecular therapies in BRAF V600E mutated thyroid cancer.